Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Publication year range
2.
J Vis Exp ; (111)2016 05 19.
Article in English | MEDLINE | ID: mdl-27286467

ABSTRACT

In spite of the success in applying non-invasive electroencephalography (EEG), magneto-encephalography (MEG) and functional magnetic resonance imaging (fMRI) for extracting crucial information about the mechanism of the human brain, such methods remain insufficient to provide information about physiological processes reflecting cognitive and emotional functions at the subcortical level. In this respect, modern invasive clinical approaches in humans, such as deep brain stimulation (DBS), offer a tremendous possibility to record subcortical brain activity, namely local field potentials (LFPs) representing coherent activity of neural assemblies from localized basal ganglia or thalamic regions. Notwithstanding the fact that invasive approaches in humans are applied only after medical indication and thus recorded data correspond to altered brain circuits, valuable insight can be gained regarding the presence of intact brain functions in relation to brain oscillatory activity and the pathophysiology of disorders in response to experimental cognitive paradigms. In this direction, a growing number of DBS studies in patients with Parkinson's disease (PD) target not only motor functions but also higher level processes such as emotions, decision-making, attention, memory and sensory perception. Recent clinical trials also emphasize the role of DBS as an alternative treatment in neuropsychiatric disorders ranging from obsessive compulsive disorder (OCD) to chronic disorders of consciousness (DOC). Consequently, we focus on the use of combined invasive (LFP) and non-invasive (EEG) human brain recordings in assessing the role of cortical-subcortical structures in cognitive and emotional processing trough experimental paradigms (e.g. speech stimuli with emotional connotation or paradigms of cognitive control such as the Flanker task), for patients undergoing DBS treatment.


Subject(s)
Cognition , Emotions , Monitoring, Physiologic , Deep Brain Stimulation , Humans , Parkinson Disease/physiopathology , Parkinson Disease/therapy , Thalamus
3.
Neuroscience ; 329: 83-92, 2016 08 04.
Article in English | MEDLINE | ID: mdl-27163379

ABSTRACT

Principles of negative reinforcement learning may play a critical role in the etiology and treatment of depression. We examined the integrity of positive reinforcement learning in congenitally helpless (cH) rats, an animal model of depression, using a random ratio schedule and a devaluation-extinction procedure. Furthermore, we tested whether an antidepressant dose of the monoamine oxidase (MAO)-B inhibitor deprenyl would reverse any deficits in positive reinforcement learning. We found that cH rats (n=9) were impaired in the acquisition of even simple operant contingencies, such as a fixed interval (FI) 20 schedule. cH rats exhibited no apparent deficits in appetite or reward sensitivity. They reacted to the devaluation of food in a manner consistent with a dose-response relationship. Reinforcer motivation as assessed by lever pressing across sessions with progressively decreasing reward probabilities was highest in congenitally non-helpless (cNH, n=10) rats as long as the reward probabilities remained relatively high. cNH compared to wild-type (n=10) rats were also more resistant to extinction across sessions. Compared to saline (n=5), deprenyl (n=5) reduced the duration of immobility of cH rats in the forced swimming test, indicative of antidepressant effects, but did not restore any deficits in the acquisition of a FI 20 schedule. We conclude that positive reinforcement learning was impaired in rats bred for helplessness, possibly due to motivational impairments but not deficits in reward sensitivity, and that deprenyl exerted antidepressant effects but did not reverse the deficits in positive reinforcement learning.


Subject(s)
Antidepressive Agents/pharmacology , Depressive Disorder/drug therapy , Helplessness, Learned , Learning Disabilities/drug therapy , Nootropic Agents/pharmacology , Selegiline/pharmacology , Animals , Appetite , Conditioning, Operant/drug effects , Disease Models, Animal , Extinction, Psychological , Male , Monoamine Oxidase Inhibitors/pharmacology , Motivation/drug effects , Motivation/physiology , Motor Activity/drug effects , Rats, Sprague-Dawley , Reinforcement, Psychology , Resilience, Psychological/drug effects , Species Specificity
4.
Cereb Cortex ; 26(7): 3000-9, 2016 07.
Article in English | MEDLINE | ID: mdl-26048953

ABSTRACT

We asked whether episodic-like memory requires neural mechanisms independent of those that mediate its component memories for "what," "when," and "where," and if neuronal connectivity between the medial prefrontal cortex (mPFC) and the hippocampus (HPC) CA3 subregion is essential for episodic-like memory. Unilateral lesion of the mPFC was combined with unilateral lesion of the CA3 in the ipsi- or contralateral hemispheres in rats. Episodic-like memory was tested using a task, which assesses the integration of memories for "what, where, and when" concomitantly. Tests for novel object recognition (what), object place (where), and temporal order memory (when) were also applied. Bilateral disconnection of the mPFC-CA3 circuit by N-methyl-d-aspartate (NMDA) lesions disrupted episodic-like memory, but left the component memories for object, place, and temporal order, per se, intact. Furthermore, unilateral NMDA lesion of the CA3 plus injection of (6-cyano-7-nitroquinoxaline-2,3-dione) (CNQX) (AMPA/kainate receptor antagonist), but not AP-5 (NMDA receptor antagonist), into the contralateral mPFC also disrupted episodic-like memory, indicating the mPFC AMPA/kainate receptors as critical for this circuit. These results argue for a selective neural system that specifically subserves episodic memory, as it is not critically involved in the control of its component memories for object, place, and time.


Subject(s)
CA3 Region, Hippocampal/metabolism , Memory, Episodic , Prefrontal Cortex/metabolism , Receptors, AMPA/metabolism , Receptors, Kainic Acid/metabolism , Animals , CA3 Region, Hippocampal/drug effects , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Male , N-Methylaspartate/metabolism , N-Methylaspartate/toxicity , Neural Pathways/drug effects , Neural Pathways/metabolism , Neurotransmitter Agents/pharmacology , Prefrontal Cortex/drug effects , Rats, Wistar , Receptors, AMPA/antagonists & inhibitors , Receptors, Kainic Acid/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/metabolism , Recognition, Psychology/drug effects , Recognition, Psychology/physiology , Time Perception/drug effects , Time Perception/physiology
5.
Cortex ; 60: 94-102, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25444578

ABSTRACT

We report on thalamic recordings in a patient with chronic disorder of consciousness (DOC). Implantation of central thalamic deep brain stimulation (CT-DBS) electrodes was chosen, as this treatment has been reported to display beneficial effects with respect to behavioural responsiveness in DOC. Local field potential (LFP) oscillations were recorded from central thalamic electrodes and their changes elicited by speech stimuli consisting either of familiar voices addressing the patient or unfamiliar non-addressing phrases were studied. In response to familiar-addressing speech we observed modulation of oscillatory activity in the beta and theta band within the central thalamus accompanied by an increase in thalamocortical coherence in the theta band. Furthermore, the theta phase was coupled to the amplitude of gamma locally in the thalamus. These findings indicate a local and long-range cross-frequency response which is not only indicative of the principle involvement of the central thalamus in processing emotional and cognitive information, but also point towards intact physiological functions that may serve as a marker in diagnosing DOC patients and determining novel targets and parameters concerning therapeutic efforts.


Subject(s)
Brain Waves/physiology , Cognition/physiology , Consciousness Disorders/physiopathology , Emotions/physiology , Thalamus/physiology , Acoustic Stimulation , Action Potentials/physiology , Brain Mapping , Consciousness Disorders/therapy , Deep Brain Stimulation , Female , Humans , Middle Aged
6.
Behav Brain Res ; 252: 58-67, 2013 Sep 01.
Article in English | MEDLINE | ID: mdl-23727148

ABSTRACT

The subthalamic nucleus (STN) has a pivotal role in the pathophysiology of Parkinson's disease (PD). Modulation of STN activity (by lesions, pharmacological or electrical stimulation) has been shown to improve motor parameters in PD patients and in animal models of PD. In an attempt to characterize the neurochemical bases for such antiparkinsonian action, we address specific neurotransmitter systems via local pharmacological manipulation of the STN in hemiparkinsonian rats. Here, we have focused on the GABAergic and glutamatergic receptors in the STN. In animals with unilateral 6-hydroxydopamine lesions of the nigro-striatal tract, we administered either the selective GABAA-agonist muscimol (0.5 µg and 1.0 µg), the non-competitive N-methyl-d-aspartate (NMDA)-antagonist MK-801 (dizocilpine; 2.5 µg), or vehicle (0.25 µl) into the STN. The effects of GABAergic and glutamatergic modulation of the STN on motor parameters were assessed by gauging rotational behavior and locomotion. Application of muscimol ipsilateral to the side of dopamine-depletion influenced turning behavior in a dose-dependent fashion, with the low dose re-adjusting turning behavior to a non-biased distribution, and the high dose evoking contraversive turning. The administration of MK-801 did not have such effects. These findings give evidence for the involvement of GABAergic activation in the STN in the compensation of motor asymmetries in the hemiparkinsonian rat, whereas N-methyl-d-aspartate (NMDA)-antagonism was ineffective in this model of PD.


Subject(s)
Functional Laterality/physiology , Mental Disorders/etiology , Parkinson Disease/complications , Receptors, GABA-A/metabolism , Subthalamic Nucleus/metabolism , 3,4-Dihydroxyphenylacetic Acid/metabolism , Adrenergic Agents/toxicity , Amphetamine , Animals , Disease Models, Animal , Dizocilpine Maleate/therapeutic use , Dopamine/metabolism , Dose-Response Relationship, Drug , Functional Laterality/drug effects , GABA-A Receptor Agonists/pharmacology , Homovanillic Acid/metabolism , Male , Medial Forebrain Bundle/drug effects , Medial Forebrain Bundle/physiology , Mental Disorders/drug therapy , Muscimol/pharmacology , Neuroprotective Agents/therapeutic use , Oxidopamine/toxicity , Parkinson Disease/drug therapy , Parkinson Disease/etiology , Rats , Rats, Wistar , Statistics, Nonparametric , Subthalamic Nucleus/drug effects , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...